CHESS / USDT

CHESS / USDC

ZIL / IDR

ZIL / USDT

ZIL / TRY

ANKR / USDT

ANKR / TRY

C98 / USDT

FRAX / USDT

DATA / USDT

GUN / BNB

ZK / BTC

ZK / USDT

ZK / TRY

ZK / USDC

FOGO / TRY

FOGO / USDT

SENT / TRY

FOGO / USDC

SENT / USDC

AVALON TECHNOLOGIES LTD

AVANTI FEEDS LIMITED

PARAMOUNT COMM LTD

INDO COUNT INDUSTRIES LTD

GARWARE HI-TECH FILMS LTD

POKARNA LIMITED

CAMLIN FINE SCIENCES LTD

ADF FOODS LIMITED

NELCAST LIMITED

KITEX GARMENTS LTD

KCK INDUSTRIES LTD

PARAS PETROFILS LTD.

MAITREYA MEDICARE LIMITED

ARTEMIS MED SERVICE LTD

MUNISH FORGE LIMITED

SAJ HOTELS LIMITED

PICTUREPOST STUDIOS LTD

ANYA POLYTECH & FERTI LTD

MPS LIMITED

FABTECH TECHNOLOGIES LTD

Click here to get full coverage on Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact - Business Standard

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact  Business Standard

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact - Business Standard

Click here to get full coverage on Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey  PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Click here to get full coverage on Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation  BW Healthcare World

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Click here to get full coverage on Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary  Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Click here to get full coverage on Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Biocon Limited to integrate Biocon Biologics  The Pharma Letter

Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Click here to get full coverage on Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale  Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Click here to get full coverage on Inclusive innovation: how Biocon brought biotech to all - Impact Economist

Inclusive innovation: how Biocon brought biotech to all  Impact Economist

Inclusive innovation: how Biocon brought biotech to all - Impact Economist

Click here to get full coverage on Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Biocon opens first US manufacturing facility in New Jersey  NJBIZ

Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Click here to get full coverage on US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says  Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

Click here to get full coverage on Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions - The Economic Times

Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions  The Economic Times

Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions - The Economic Times

Click here to get full coverage on Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ  Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Click here to get full coverage on Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion  Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Click here to get full coverage on Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury  New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Click here to get full coverage on Amgen Expands US BPCIA Denosumab Litigation to include Biocon - Pearce IP

Amgen Expands US BPCIA Denosumab Litigation to include Biocon  Pearce IP

Amgen Expands US BPCIA Denosumab Litigation to include Biocon - Pearce IP

Click here to get full coverage on Biocon Receives VAI Status From US FDA For Andhra Pradesh Facility - TradingView

Biocon Receives VAI Status From US FDA For Andhra Pradesh Facility  TradingView

Biocon Receives VAI Status From US FDA For Andhra Pradesh Facility - TradingView

Click here to get full coverage on Watch Biocon Biologics CEO Discusses Merger and IPO Plans - Bloomberg.com

Watch Biocon Biologics CEO Discusses Merger and IPO Plans  Bloomberg.com

Watch Biocon Biologics CEO Discusses Merger and IPO Plans - Bloomberg.com

Click here to get full coverage on Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea  Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Click here to get full coverage on Samsung Biologics, Amgen and Biocon invest in US pharma sites - Yahoo Finance

Samsung Biologics, Amgen and Biocon invest in US pharma sites  Yahoo Finance

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Yahoo Finance

Click here to get full coverage on Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited  PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Click here to get full coverage on Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg.com

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion  Bloomberg.com

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg.com

Click here to get full coverage on Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US  Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Click here to get full coverage on Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - Yahoo Finance

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options  Yahoo Finance

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - Yahoo Finance

Click here to get full coverage on Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives  PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Click here to get full coverage on Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026  Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Click here to get full coverage on Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Click here to get full coverage on Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review - The Economic Times

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review  The Economic Times

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review - The Economic Times

Click here to get full coverage on Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says  Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Click here to get full coverage on ‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push - Citeline News & Insights

‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push  Citeline News & Insights

‘You Control Your Destiny’ – CEO Mittal On Biocon’s US Manufacturing Push - Citeline News & Insights

Click here to get full coverage on Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases  Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Click here to get full coverage on Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - lamag.com

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients  lamag.com

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - lamag.com

Click here to get full coverage on Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio  PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Click here to get full coverage on Biocon to merge biologics unit in $5.5 billion deal - Times of India

Biocon to merge biologics unit in $5.5 billion deal  Times of India

Biocon to merge biologics unit in $5.5 billion deal - Times of India

Click here to get full coverage on Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio,  GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Click here to get full coverage on Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara® - Yahoo! Finance Canada

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®  Yahoo! Finance Canada

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara® - Yahoo! Finance Canada

Click here to get full coverage on Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti - CNBC TV18

Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti  CNBC TV18

Budget 2026: Biocon shares gain after FM Nirmala Sitharaman announces ₹10,000 crore for Biopharma Shakti - CNBC TV18

Click here to get full coverage on Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California - Pearce IP

Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California  Pearce IP

Biocon Partners with Civica on Insulin Glargine Biosimilar; US$11 per Pen Pricing in California - Pearce IP

Click here to get full coverage on Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Biocon secures global rights to biosimilar adalimumab  The Pharma Letter

Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Click here to get full coverage on Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; - Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%;  Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; - Biocon

Click here to get full coverage on Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.  PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Click here to get full coverage on Biocon Biologics receives MHRA approval for Yesintek - The Pharma Letter

Biocon Biologics receives MHRA approval for Yesintek  The Pharma Letter

Biocon Biologics receives MHRA approval for Yesintek - The Pharma Letter

Click here to get full coverage on Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*; - Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*;  Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*; - Biocon

Click here to get full coverage on Bengaluru shocker: 26-year-old Biocon employee dies after jumping from office building - Times of India

Bengaluru shocker: 26-year-old Biocon employee dies after jumping from office building  Times of India

Bengaluru shocker: 26-year-old Biocon employee dies after jumping from office building - Times of India

Click here to get full coverage on Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026 - Upstox

Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026  Upstox

Biocon other pharma stocks surge after FM Sitharaman proposes ₹10,000 crore for building biosimilars, biologics in Budget 2026 - Upstox

Click here to get full coverage on In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay - TradingView

In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay  TradingView

In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay - TradingView

Click here to get full coverage on Biocon Denosumab biosimilars receive EU marketing authorisation - Pharmaceutical Technology

Biocon Denosumab biosimilars receive EU marketing authorisation  Pharmaceutical Technology

Biocon Denosumab biosimilars receive EU marketing authorisation - Pharmaceutical Technology

Click here to get full coverage on Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics - Medical Dialogues

Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics  Medical Dialogues

Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics - Medical Dialogues

Click here to get full coverage on Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B  Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Click here to get full coverage on Biocon clears US path for denosumab biosimilars - The Pharma Letter

Biocon clears US path for denosumab biosimilars  The Pharma Letter

Biocon clears US path for denosumab biosimilars - The Pharma Letter

Click here to get full coverage on FDA Approves Biocon’s Denosumab Biosimilars Bosaya™ and Aukelso™ - Pearce IP

FDA Approves Biocon’s Denosumab Biosimilars Bosaya™ and Aukelso™  Pearce IP

FDA Approves Biocon’s Denosumab Biosimilars Bosaya™ and Aukelso™ - Pearce IP

Click here to get full coverage on Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States  PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Click here to get full coverage on Biocon to introduce Keytruda among three new oncology biosimilars at JPM 2026 - ET Pharma

Biocon to introduce Keytruda among three new oncology biosimilars at JPM 2026  ET Pharma

Biocon to introduce Keytruda among three new oncology biosimilars at JPM 2026 - ET Pharma

Click here to get full coverage on Biocon to merge biologics unit in $5.5 billion deal - Mint

Biocon to merge biologics unit in $5.5 billion deal  Mint

BIOCON

Price Chart

Key Statistics

Technicals

About BIOCON

Latest News

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact - Business Standard

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Scaling With Purpose: How Biocon Biologics Is Using Scale To Expand Access And Drive Innovation - BW Healthcare World

Advanced Charts

Top Gainers

Top Losers